ClinicalTrials.gg
RecruitingNCT06061042TREATUpdated Sep 29, 2023

Effect of Timed-Restricted Eating on Metabolic Health

An interventional study of Early time restricted eating and Late time restricted eating in Obesity, Non-Alcoholic Fatty Liver Disease and Insulin Resistance, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Obesity with a site in Netherlands — 43 open to participants now, 55 under way, 14 of them phase 3. Obesity · Netherlands.

Planned enrollment
150th of 211
30 · median 58
Started
2023
with 10 others
No phase
128 of 248
17 open now
Primary completion
2027-12
later than 29 of 54 live
Registered
196th of 248
by date
Lead sponsor
9 of 248
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 248 studies in Obesity with a site in Netherlands, this one is the 150th largest by planned enrollment of the 211 interventional ones that give a count, is one of 11 that started in 2023, is one of 128 with no phase, reaches primary completion later than 29 of the 54 other live ones, and was the 196th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

43 of the 248 studies in Obesity with a site in Netherlands are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Obesity with a site in Netherlands, or all of them as a file.
02

Study summary

We aim to determine the effect of combined isocaloric time restricted eating and meal timing on metabolic health, liver fat, functional brain networks, inflammation, and sleep pattern/quality in subjects with obesity and insulin resistance.

Read the detailed description

Obesity is an alarming global health issue, with increasing prevalence. Obesity leads to a vast array of disorders, including dyslipidemia, the accumulation of intrahepatic triglycerides (IHTG), multiorgan insulin resistance and type 2 diabetes mellitus. In addition, disruption of the circadian rhythm (circadian misalignment), which is associated with irregular eating schedules, is an important risk factor for the development of obesity, IHTG and type 2 diabetes mellitus. Time restricted eating (TRE) is a form of intermittent fasting, in which the daily eating period is restricted. The beneficial effect of this type of diet might relate to adequate synchronization of food intake and fasting to the internal rhythm of the circadian tissue clocks, improving metabolic handling of nutrients and metabolic flexibility.

03

Conditions studied

  • Obesity
  • Non-Alcoholic Fatty Liver Disease
  • Insulin Resistance
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to provide ;
  • > 30kg/m\^2;
  • Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and \< 7.0 mmol/L;
  • Stable weight for 3 months prior to study inclusion
  • For women, 1 year after last menstrual cycle

Exclusion criteria

Exclusion Criteria:

  • Use of any medication, except for those related to treatment of metabolic syndrome;
  • Any medical condition interfering with study outcomes or design;
  • History of any psychiatric disorder, including eating disorders;
  • Performing shift work
  • Performing intensive sports (>3 hours/week);
  • Smoking;
  • Drugs abuse or alcohol abuse (>3 units/day);
  • for MRI;
  • Known lactose/gluten intolerance;
  • Known soy, egg, milk or peanut allergy;
  • Childhood onset of obesity
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Early time-restricted eating

    * 50% of daily calories at breakfast, 35% at lunch and 15% at dinner. 85% of calories consumed in 6h, i.e., between 7AM and 1PM. * Eating period, 10h (7AM-5PM); fasting period, 14h; Breakfast between 7 and 8 AM; lunch between 12 AM and 1 PM; dinner between 4 and 5 PM.

    Behavioral: Early time restricted eating

  • Experimental
    Late time-restricted eating

    * 15% of daily calories at breakfast, 35% at lunch and 50% at dinner. 85% of calories consumed in 6h, i.e., between 2PM and 8PM. * Eating period, 10h (10AM-8PM), fasting period, 14h; Breakfast between 10 and 11 AM; lunch between 2 and 3 PM; dinner between 7 and 8 PM.

    Behavioral: Late time restricted eating

Interventions

  • BehavioralEarly time restricted eating

    Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the early-TRE group is between 7 AM - 5 PM

    Also known as: early-TRE

  • BehavioralLate time restricted eating

    Subjects will follow an isocaloric diet, designed by a dietician. The eating window for the late-TRE group is between 10 AM - 8 PM

    Also known as: late-TRE

06

What researchers measure

Primary outcomes

  1. Insulin Sensitivity

    We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity. Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model. The output is in dl/kg/min/uU/ml.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

Secondary outcomes

  1. Change in plasma insulin

    Fasted and stimulated insulin (pmol/L) will be measured during MMTT

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  2. Change in plasma glucose

    Fasted and stimulated glucose (mmol/L) will be measured during MMTT

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  3. Change in intrahepatic fat

    To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used. Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak. This will also be corrected for T2 relaxation.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  4. Change in beta cell function (C-peptide)

    Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  5. Change in insulin aignaling

    Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  6. Change in glucose variability

    In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention. These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels. This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.

    Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

  7. De novo lipogenesis

    Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  8. Immunological markers

    We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types. Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs). Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  9. Physical activity

    Physical activity will be assessed via accelerometry. Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.

    Time frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2

  10. Functional brain activity

    Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  11. Psychological factor - Food Craving

    We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants. The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  12. Psychological factor - Eating behaviour

    We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants. The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating. A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  13. Psychological factor - Hunger scale

    We will employ a nine-question visual analogue scale (VAS) to assess hunger. Each question will be scored 0-100.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  14. Psychological factor - Food addiction

    We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours. The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  15. Psychological factor - Impulsiveness

    We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food. This will help us understand how impulsivity might influence dietary behaviour. The score ranges from 30-120 and a higher score leans towards greater impulsivity.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  16. Psychological factor - Chronotype

    To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ). This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  17. Subject experience with intervention

    We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  18. Delay discounting computational task

    The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices. In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

  19. Iowa gambling computational task

    We use the Iowa gambling task to assess decision-making and risk-reward sensitivity. Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings. We use this task to study risk taking and impulsive behaviour.

    Time frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Dec 2027, 50 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 50 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2023
First posted
Sep 29, 2023
StartEst.
Oct 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06061042
Collaborators
Diabetesfonds
Responsible party
Prof. Dr. Mireille JM Serlie (MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Sep 29, 2023
Start date
Oct 2023 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 29, 2023

Study contacts

Jur Kroon, BSc
Contact
jur.kroon@amsterdamumc.nl
+31 683238752
Sarah E Siegelaar, MD PhD
Contact
s.e.siegelaar@amsterdamumc.nl
Mireille JM Serlie, MD PhD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion